Literature DB >> 2896036

Chronic prazosin attenuates the natriuretic response to a modest saline load in anaesthetized rats.

S B Penner1, D D Smyth.   

Abstract

1. The effect of chronic prazosin pretreatment (3 days) on the ability to excrete a modest saline load (i.v. saline, 0.097 ml min-1) was studied in the anaesthetized rat. Three days before the experiment, the drinking water was replaced with 0.5% dextrose (control), 0.015 mg ml-1 prazosin in 0.5% dextrose (low dose) or 0.15 mg ml-1 prazosin in 0.5% dextrose (high dose). 2. The selectivity of the prazosin for alpha 1-adrenoceptors was evaluated in pithed rats. The pressor response to phenylephrine was partially attenuated by the low dose of prazosin and completely attenuated by the high dose of prazosin. The pressor response to clonidine was slightly decreased by the 3 day prazosin pretreatment indicating a selectivity for alpha 1-adrenoceptors. 3. In rats pretreated with the low dose of prazosin, there was a significant decrease in sodium and water, but not potassium excretion as compared to the control group. Captopril failed to alter these effects of the low dose of prazosin. Blood pressure and creatinine clearance were the same in both groups. In rats pretreated with the high dose of prazosin, there was a further decrease in sodium and water but not potassium excretion. However, this dose of prazosin also significantly decreased blood pressure and increased creatinine clearance. A decrease in renal perfusion pressure with an aortic clamp to the same level as that observed with the high prazosin dose also decreased sodium and water but not potassium excretion. The decrease in sodium and water excretion was not as great as that observed with the high dose of prazosin. 4. The results indicate that chronic a,-adrenoceptor blockade with prazosin attenuates the ability to excrete a saline load in a dose-related manner. Whether this inability to excrete a saline load is analogous to the sodium and water retention observed with the clinical use of prazosin remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896036      PMCID: PMC1853794          DOI: 10.1111/j.1476-5381.1988.tb11452.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  22 in total

Review 1.  Drug therapy. Prazosin.

Authors:  J Koch-Weser; R M Graham; W A Pettinger
Journal:  N Engl J Med       Date:  1979-02-01       Impact factor: 91.245

2.  Blood volume, the venous system, preload, and cardiac output.

Authors:  C V Greenway; W W Lautt
Journal:  Can J Physiol Pharmacol       Date:  1986-04       Impact factor: 2.273

3.  New method for direct determination of "true" creatinine.

Authors:  H Yatzidis
Journal:  Clin Chem       Date:  1974-09       Impact factor: 8.327

4.  Renal function in conscious rats with chronic unilateral renal denervation.

Authors:  P R Rogenes; C W Gottschalk
Journal:  Am J Physiol       Date:  1982-02

5.  Prazosin and renal hemodynamics: arteriolar vasodilation during therapy of essential hypertension in man.

Authors:  R A Preston; D T O'Connor; R A Stone
Journal:  J Cardiovasc Pharmacol       Date:  1979 May-Jun       Impact factor: 3.105

6.  Aldosterone in the exaggerated natriuresis of spontaneously hypertensive rats.

Authors:  L R Willis; J H Bauer
Journal:  Am J Physiol       Date:  1978-01

7.  Physiologic evaluation of a new antihypertensive agent: prazosin HCl.

Authors:  M C Koshy; D Mickley; J Bourgiognie; M D Blaufox
Journal:  Circulation       Date:  1977-03       Impact factor: 29.690

8.  Renal nerve activity and exaggerated natriuresis in conscious spontaneously hypertensive rats.

Authors:  S E Ricksten; T Yao; G F di Bona; P Thorén
Journal:  Acta Physiol Scand       Date:  1981-06

9.  Physiologic mechanisms opposing the hemodynamic effects of prazosin.

Authors:  J L Izzo; D Horwitz; H R Keiser
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

Review 10.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

View more
  1 in total

1.  The role of the peripheral sympathetic nervous system in the natriuresis following central administration of an I1 imidazoline agonist, moxonidine.

Authors:  S B Penner; D D Smyth
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.